Sequence: Proprietary cyclic CPP (sequence not disclosed)
PMO (antisense oligonucleotide)
| Experiment Id | EXP001252 |
|---|---|
| Paper | The endosomal escape vehicle platform enhances delivery of oligonucleotides in preclinical models of |
| Peptide | EEV1 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 0.6 µM (PMO equiv; also tested up to 10 µM) |
| Mixing Ratio | |
| Formulation Format | covalent peptide–PMO conjugate |
| Formulation Components | EEV1-PMO654 |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa EGFP-654 cells |
| Animal Model | |
| Administration Route | |
| Output Type | splice correction / reporter expression |
| Output Value | Dose-dependent EGFP restoration; 0.6 µM EEV1-PMO654 ~ similar to 20 µM naked PMO654 |
| Output Units | |
| Output Notes | EGFP restored by flow cytometry and live-cell fluorescence microscopy; splice switching shown by RT-PCR. |
| Toxicity Notes | |
| Curation Notes |